Lower expression levels of Tim-3 on PBMCs are associated with an increased possibility of progression to secondary progressive multiple sclerosis (SPMS), while higher Tim-3 expression levels on PBMCs are associated with a benign prognosis 10 years later (56). The gene discussed is HAVCR2; the disease is secondary progressive multiple sclerosis.